These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 38263684)
1. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study. Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684 [TBL] [Abstract][Full Text] [Related]
2. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease. Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426 [TBL] [Abstract][Full Text] [Related]
4. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study. Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992 [TBL] [Abstract][Full Text] [Related]
5. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. Sergi CM Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031 [TBL] [Abstract][Full Text] [Related]
6. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics. Park H; Kim M; Kim HL; Cho S; Yoon EL; Jun DW Hepatol Res; 2024 Nov; 54(11):1027-1034. PubMed ID: 38703383 [TBL] [Abstract][Full Text] [Related]
8. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116 [TBL] [Abstract][Full Text] [Related]
9. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142 [TBL] [Abstract][Full Text] [Related]
10. From NAFLD to MASLD: When metabolic comorbidity matters. Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250 [TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V; J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486 [TBL] [Abstract][Full Text] [Related]
17. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759 [TBL] [Abstract][Full Text] [Related]
18. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan. Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312 [TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)]. Canivet CM; Faure S Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295 [TBL] [Abstract][Full Text] [Related]